Cleared Traditional

LEININGEO AORTIC PUNCH #310-395 & 397 (K771625) - FDA 510(k) Clearance

Class I Cardiovascular device.

K771625 · J. Jamner Surgical Instruments, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1977
Decision
18d
Days
Class 1
Risk

K771625 is an FDA 510(k) clearance for the LEININGEO AORTIC PUNCH #310-395 & 397. Classified as Instruments, Surgical, Cardiovascular (product code DWS), Class I - General Controls.

Submitted by J. Jamner Surgical Instruments, Inc. (Mchenry, US). The FDA issued a Cleared decision on September 12, 1977 after a review of 18 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.4500 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all J. Jamner Surgical Instruments, Inc. devices

Submission Details

510(k) Number K771625 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 25, 1977
Decision Date September 12, 1977
Days to Decision 18 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
107d faster than avg
Panel avg: 125d · This submission: 18d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code DWS Instruments, Surgical, Cardiovascular
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 870.4500
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.